Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7926751 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4ALOX5APFEN1GPR119 | |
| SCHEMBL13335385 | 0.95 | CHRNB2 (0.46) | CHRNB2CHRNA4ALOX5APFEN1GPR119 | |
| SCHEMBL13335360 | 0.95 | CHRNB2 (0.43) | CHRNB2CHRNA4ALOX5APFEN1GPR119 | |
| SCHEMBL13335353 | 0.95 | CHRNB2 (0.43) | CHRNB2CHRNA4ALOX5APFEN1GPR119 | |
| SCHEMBL3361912 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4ALOX5APFEN1CHRNB4 | |
| SCHEMBL3356859 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4ALOX5APFEN1GPR119 | |
| SCHEMBL3360739 | 0.88 | CHRNB2 (0.43) | CHRNB2CHRNA4ALOX5APFEN1GPR119 | |
| SCHEMBL3356642 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4ALOX5APFEN1CHRNB4 | |
| SCHEMBL3358841 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4ALOX5APFEN1CHRNB4 | |
| SCHEMBL13308485 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4ALOX5APFEN1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885ALOX5AP 1182/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885ALOX5AP 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.